Back to search
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trials you may qualify forThis study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's p…
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses…
This prospective observational study will evaluate quality of life, functional status, and cognitive outcomes in men with metastatic hormone-sensitive prostate…
This is an observational study in which medical records of Japanese men with low-volume metastatic hormone-sensitive prostate cancer (mHSPC), who received treat…
Prostate cancer is the most common non-skin cancer among men in the United States. For some men, the cancer has already spread to other parts of the body at the…
The purpose of this study is to assess the real-world outcomes differences between apalutamide or enzalutamide plus androgen deprivation therapy (ADT) for the t…
The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants…